Gaia Alberti

Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going?

M. Serafini, A. Biondi, G. Gaipa, 2020, Cells.

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway

H. Baelde, A. Kruisselbrink, J. Bovée, 2019, Journal of bone oncology.

Acute myeloid leukaemia niche regulates response to L‐asparaginase

L. Antolini, M. Serafini, C. Gambacorti-Passerini, 2019, British journal of haematology.

A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival

A. Cleton-Jansen, E. Danen, B. van de Water, 2019, Journal of bone oncology.

Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.

Z. Izsvák, S. Galimberti, M. Valsecchi, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche

M. Serafini, F. Mantegazza, F. Dazzi, 2023, Frontiers in Immunology.

Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

B. Falini, S. Galimberti, F. Morena, 2022, Blood.

IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML

B. Falini, S. Galimberti, F. Morena, 2022, Blood advances.